Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)

This study (called PrEcISE) is testing whether customizing the antidepressant escitalopram based on a teenager's genetics can improve its effectiveness and reduce side effects for adolescents with anxiety disorders. **You may be eligible if...** - You are between 12 and 17 years old - You (and your parent/guardian) are fluent in English and can provide consent and assent - You have been diagnosed with generalized anxiety disorder, social anxiety disorder, or separation anxiety disorder - Your anxiety is moderate to severe based on clinical rating scales - You are not starting new therapy within 8 weeks of screening, or your current therapy has been stable for at least 2 months **You may NOT be eligible if...** - You have significant medical or laboratory abnormalities - You have a psychiatric condition other than anxiety (such as psychosis or bipolar disorder) - You are pregnant - You have a significant history of suicidal behavior Talk to your doctor to see if this trial is right for you.